Stocks making the biggest moves premarket: Lockheed Martin, Tesla, Alphabet & more

Premarket movers were mixed: Tesla shares fell nearly 6% after a Q2 earnings miss and free cash flow turning negative as margins pressured. Alphabet dropped 4.5% after raising its 2026 capex outlook to $195B–$205B (from up to $190B) to bolster AI efforts, while Lockheed Martin jumped 6% on Q2 results that beat expectations ($7.94 EPS vs $7.19 consensus on $20.06B revenue vs $19.34B). IBM slid after its Q2 profit and revenue came in below forecasts, and Texas Instruments topped estimates (EPS $2.14 vs $1.93; revenue $5.46B vs $5.25B) despite shares down 3.2%; Eli Lilly was steady/slightly down after outlining plans to seek approval for a next-gen obesity drug in Q1 2027 following late-stage trial results.

Analysis

The market is separating quality of growth from headline growth. Tesla’s negative free cash flow shifts the debate from unit growth to self-funding ability; if margins stay under pressure for another 1-2 quarters, the equity can de-rate faster than earnings because investors lose confidence in the path to durable cash generation. Alphabet’s higher AI spend is the mirror image: near-term FCF dilution, but a stronger competitive moat if the spend translates into search/cloud share defense; the biggest second-order winners are the AI infrastructure suppliers and power/cooling chain, not necessarily GOOGL itself.

Lockheed is the cleaner fundamental read-through: defense is one of the few large-cap sectors where incremental revenue still converts into forward guidance, so relative flows should favor LMT over capital-intensive growth names. Eli Lilly is more of a long-dated option on category expansion than a near-term P&L event; the real implication is that obesity remains a multi-year battleground, which keeps pressure on rivals like NVO and on payers/pharmacies if efficacy improves enough to broaden access. The 2027 approval timeline means today’s move is mostly signaling rather than monetizable cash flow.

IBM and Texas Instruments look like different versions of the same problem: the market is not paying up for “beats” when it doubts the forward demand curve. For TXN, the down move may be overdone if analog inventory digestion is nearing its end and auto/industrial orders stabilize over the next 1-2 quarters. Contrarian takeaway: the consensus may be too punitive on capex-heavy AI spend and too generous on Tesla’s margin recovery assumptions; the spread between cash generative defensives and self-funding-risk stories should widen if rates stay elevated.

Key Decisions for Investors

• Go long LMT vs short TSLA for 1-3 months: trade quality cash conversion against deteriorating margin/FCF credibility; target 8-12% relative outperformance if Tesla guidance remains soft.
• Buy a basket of AI infrastructure beneficiaries on GOOGL weakness (e.g., NVDA/AVGO/ANET) over 1-3 months: higher hyperscaler capex is a demand tailwind for picks-and-shovels even if it pressures GOOGL FCF.
• Start a tactical long in TXN on weakness for a 3-6 month rebound: if channel inventory clears and industrial demand stabilizes, the downside should be limited versus the current post-earnings selloff.
• Avoid chasing IBM on any bounce until organic growth and FCF re-accelerate: use rallies to fade unless management proves the AI story is translating into durable revenue.
• Treat LLY as a long-dated call on obesity market expansion, not a near-term catalyst trade; prefer waiting for approval/data milestones before adding size.